Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Fimepinostat with venetoclax in R/R lymphoma

Anas Younes • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Fimepinostat Venetoclax
CUDC-907-101

Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines the interesting synergistic anti-tumor effects of fimepinostat (CUDC-907), a dual inhibitor of phosphotidyl-inositol-3-kinases (PI3Ks) and Class I and II histone deacetylases (HDACs), in combination with venetoclax, a BCL2 inhibitor. This novel combination targeting MYC and BCL2 was recently evaluated in a phase 1/2, multi-center, dose-finding trial (NCT01742988), in patients with relapsed/refractory (R/R) lymphoma, R/R diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Anas Younes

Atezolizumab plus R-CHOP in DLBCL: encouraging results
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018
Anas Younes: two practice-changing abstracts at ASH 2018
1:05
Anas Younes: two practice-changing abstracts at ASH 2018
Anas Younes • 6 Dec 2018

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals